Improvement in our knowledge of gene mutations in AML has further complicated the baseline prognostic assessment of these patients, that should now include FLT3, NPM1, CEBPA, as well as RUNX1, DNMT3A, IDH1, IDH2, TET2, ASXL1 and TP53 [2,3]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.